Marcus Anthony Urey, MD presented data on GI AEs in the HELIOS-B trial

#HFSA2025
#MedIQHFSA2025

We presented exploratory data from ATTRibute-CM looking at all events - CVM and recurrent CVH - which show early and sustained effect of acoramidis throughout the study.

#HFSA2025
#MedIQHFSA2025

Ronald Witteles, MD presented on outcomes of vutrisiran monotherapy (vs placebo) in HELIOS-B with and without censoring tafamidis drop ins

#HFSA2025
#MedIQHFSA2025

Emily Martin presented on correlation of Tc-99m p5+14 in cardiac amyloidosis with clinical markers

#HFSA2025
#MedIQHFSA2025

Continues acoramidis reduced ACM/CVH from the parent study to the OLE portion at Month 42

#HFSA2025
#MedIQHFSA2025

Data from ATTRibute-CM on acoramidis potentially preventing the progression of conduction disease as part of ATTR-CM presented at #HFSA2025

#MedIQHFSA2025

Data from ATTRibute-CM on the NTproBNP response in the subgroup of variant ATTR patients. Acoramidis mitigated the rise of NTproBNP as compared to placebo

#HFSA2025
#MedIQHFSA2025

Large dataset on V122I both homozygous and heterozygous from the VA presented at #HFSA2025

#MedIQHFSA2025

Efficacy of vutrisiran in HELIOS-B by baseline health status (KCCQ) - consistent effects across the different categories analyzed

#HFSA2025
#MedIQHFSA2025

Thank you to Ahmad Masri, MD, for his live updates on emerging and potentially practice-changing clinical data on advances in the treatment of #ATTR-CM from #HFSA2025.

Check out this thread for highlights.

#MedIQHFSA2025